公开(公告)号：US20120251449A1

公开(公告)日：2012-10-04

申请号：US13510398

申请日：2010-12-22

申请人： Vijaya Raj Kuniyil Kulangara ,  Alan Cuthbertson ,  Peter Iveson ,  Chitralekha Rangaswamy ,  Veena Rao ,  Rajiv Bhalla

发明人： Vijaya Raj Kuniyil Kulangara ,  Alan Cuthbertson ,  Peter Iveson ,  Chitralekha Rangaswamy ,  Veena Rao ,  Rajiv Bhalla

IPC分类号： A61K51/04 ,  C07C47/55 ,  A61P35/00 ,  C07C223/06 ,  C07C223/04 ,  C07C47/353

CPC分类号： A61K31/136 ,  A61K51/04

摘要： The present invention claims fluoro- & iodo-containing aldehydes as ALDH substrates for use as diagnostic imaging agents or as therapeutic agents. The aldehydes are both directly and indirectly attached to an aromatic or a straight chain ring. ALDH activity was monitored either by the formation of acid-product or consumption of aldehyde substrates.

摘要翻译： 本发明要求氟 - 碘基醛作为ALDH底物用作诊断显像剂或作为治疗剂。 醛直接和间接连接到芳环或直链环上。 通过酸产物的形成或醛底物的消耗来监测ALDH活性。

公开(公告)号：US20110027814A1

公开(公告)日：2011-02-03

申请号：US12591495

申请日：2009-11-20

申请人： Veena Rao

发明人： Veena Rao

IPC分类号： C12Q1/66 ,  C12Q1/02 ,  G01N33/53

CPC分类号： C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/142

摘要： Assays using binding studies involving function of BRCA1a protein have use for diagnosis and for evaluation of possible tumorogenicity of agents, particularly estrogenic agents. The assays do not rely on use of a probe for only specific sequences, but on effects of known and unknown or not previously studied sequences (consequence of genetic changes) or posttranslational modification of BRCA1 proteins (as a consequence of epigenetic changes) as seen in hereditary and sporadic cancers.

摘要翻译： 使用涉及BRCA1a蛋白功能的结合研究的测定法可用于诊断和评估药剂，特别是雌激素剂的可能的致瘤性。 测定不依赖于仅针对特定序列使用探针，而是依赖已知和未知或未曾研究的序列（遗传变化的后果）或BRCA1蛋白翻译后修饰（作为表观遗传变化的结果）的影响，如 遗传性和散发性癌症。

公开(公告)号：US08372580B2

公开(公告)日：2013-02-12

申请号：US12591495

申请日：2009-11-20

申请人： Veena Rao

发明人： Veena Rao

IPC分类号： C12Q1/00 ,  C12Q1/66

CPC分类号： C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/142

摘要： Assays using binding studies involving function of BRCA1a protein have use for diagnosis and for evaluation of possible tumorogenicity of agents, particularly estrogenic agents. The assays do not rely on use of a probe for only specific sequences, but on effects of known and unknown or not previously studied sequences (consequence of genetic changes) or posttranslational modification of BRCA1 proteins (as a consequence of epigenetic changes) as seen in hereditary and sporadic cancers.

摘要翻译： 使用涉及BRCA1a蛋白功能的结合研究的测定法可用于诊断和评估药剂，特别是雌激素剂的可能的致瘤性。 测定不依赖于仅针对特定序列使用探针，而是依赖已知和未知或未曾研究的序列（遗传变化的后果）或BRCA1蛋白翻译后修饰（作为表观遗传变化的结果）的影响，如 遗传性和散发性癌症。